• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    TG Therapeutics, Inc. (TGTX)

    -NasdaqCM
    9.11 Down 0.31(3.29%) Apr 29, 4:00PM EDT
    |After Hours : 9.11 0.00 (0.00%) Apr 29, 4:55PM EDT
    ProfileGet Profile for:
    TG Therapeutics, Inc.
    3 Columbus Circle
    15th Floor
    New York, NY 10019
    United States - Map
    Phone: 212-554-4484
    Fax: 212-554-4531
    Website: http://www.tgtherapeutics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:30

    Business Summary 

    TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. It develops TG-1101 (ublituximab), a novel glycol engineered monoclonal antibody that targets a epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop the inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4); and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101; Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; and Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology. It also has a collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. is headquartered in New York, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on TG Therapeutics, Inc.

    Corporate Governance 
    TG Therapeutics, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 9; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Michael S. Weiss Esq., 50
    Exec. Chairman, Chief Exec. Officer and Interim Pres
    472.00K0.00
    Mr. Sean A. Power CPA, 34
    Chief Financial Officer, Treasurer and Sec.
    230.00K0.00
    Jenna Bosco ,
    Director of Investor Relations
    N/AN/A
    Dr. Robert Niecestro Ph.D., 65
    Exec. VP of Clinical and Regulatory
    N/AN/A
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders